633303-90-9Relevant academic research and scientific papers
Palladium-Catalyzed Direct C2-Biarylation of Indoles
Murugesan, Tamilarasu,Sivarajan, Chinraj,Jayakumari, Chithra Mohan,Singh, Rajat Kumar,Vennapusa, Sivaranjana Reddy,Kaliyamoorthy, Alagiri
supporting information, p. 10838 - 10851 (2021/08/16)
Biaryl and indole units are important structural motifs in several bioactive molecules and functional materials. We have accomplished straightforward access to C2-biarylated indole derivatives through palladium-catalyzed C-H activation strategy with a bro
Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT6 agonists
Bernotas, Ronald C.,Lenicek, Steven,Antane, Schuyler,Cole, Derek C.,Harrison, Boyd L.,Robichaud, Albert J.,Zhang, Guo Ming,Smith, Deborah,Platt, Brian,Lin, Qian,Li, Ping,Coupet, Joseph,Rosenzweig-Lipson, Sharon,Beyer, Chad E.,Schechter, Lee E.
experimental part, p. 5153 - 5163 (2009/12/09)
A series of 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines 10a-z was prepared as novel 5-HT6 ligands. The best compounds were high affinity, full agonists at 5-HT6 receptors. Several agonists demonstrated good selectivity over other serotonergic and dopaminergic receptors. Acute administration of selective agonist 10e significantly increased extracellular GABA concentrations in rat frontal cortex. This compound also reduced adjunctive drinking behavior in the rat schedule-induced polydipsia assay, possibly predictive of efficacy in obsessive compulsive disorder and other anxiety related disorders.
Discovery of 4-azaindoles as novel inhibitors of c-Met kinase
Porter, John,Lumb, Simon,Franklin, Richard J.,Gascon-Simorte, Jose M.,Calmiano, Mark,Riche, Kelly Le,Lallemand, Benedicte,Keyaerts, Jean,Edwards, Helen,Maloney, Alison,Delgado, Jean,King, Lloyd,Foley, Anne,Lecomte, Fabien,Reuberson, James,Meier, Christoph,Batchelor, Mark
scheme or table, p. 2780 - 2784 (2009/12/25)
A series of 4-azaindole inhibitors of c-Met kinase is described. The postulated binding mode was confirmed by an X-ray crystal structure and series optimisation was performed on the basis of this structure. Future directions for series development are dis
1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
-
Page/Page column 10, (2008/06/13)
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
-
, (2008/06/13)
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
-
Page 22-23, (2008/06/13)
The present invention provides a compound of formula (I) and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
